Effect of neoadjuvant Degarelix on MRI-guided transurethral ultrasound ablation in patients with intermediate-risk prostate cancer: A pilot study

Conditions

Intermediate-risk prostate cancer

Brief summary

To measure prostate and tumor volume change after neoadjuvant ADT using T2-weighted MRI., To measure tumor-capsule contact length change after neoadjuvant ADT using T2-weighted MRI., To measure the change in vascular perfusion to the prostate and tumor after neoadjuvant ADT using dynamic contrast-enhanced T1-weighted MRI., To evaluate tissue structural changes after neoadjuvant ADT using quantitative analysis of the prostate’s intensity, shape, and texture on T2-weighted, quantitative T2 relaxation time mapping, and diffusion-weighted MRI., To measure thermal coverage of the target volume achieved by whole-gland TULSA by comparing physician-defined target boundaries to MRI measurements of temperature distributions, thermal dose distributions, and acute treatment-induced perfusion defect., To evaluate the subsequent safety, oncological, and quality-of-life outcomes of these patients for a period of 5 years.

Related papers

No related papers found yet.

Interventions

DRUGFIRMAGON 80 mg powder and solvent for solution for injection

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To measure prostate and tumor volume change after neoadjuvant ADT using T2-weighted MRI., To measure tumor-capsule contact length change after neoadjuvant ADT using T2-weighted MRI., To measure the change in vascular perfusion to the prostate and tumor after neoadjuvant ADT using dynamic contrast-enhanced T1-weighted MRI., To evaluate tissue structural changes after neoadjuvant ADT using quantitative analysis of the prostate’s intensity, shape, and texture on T2-weighted, quantitative T2 relaxation time mapping, and diffusion-weighted MRI., To measure thermal coverage of the target volume achieved by whole-gland TULSA by comparing physician-defined target boundaries to MRI measurements of temperature distributions, thermal dose distributions, and acute treatment-induced perfusion defect., To evaluate the subsequent safety, oncological, and quality-of-life outcomes of these patients for a period of 5 years.	—

Measure

Time frame

To measure prostate and tumor volume change after neoadjuvant ADT using T2-weighted MRI., To measure tumor-capsule contact length change after neoadjuvant ADT using T2-weighted MRI., To measure the change in vascular perfusion to the prostate and tumor after neoadjuvant ADT using dynamic contrast-enhanced T1-weighted MRI., To evaluate tissue structural changes after neoadjuvant ADT using quantitative analysis of the prostate’s intensity, shape, and texture on T2-weighted, quantitative T2 relaxation time mapping, and diffusion-weighted MRI., To measure thermal coverage of the target volume achieved by whole-gland TULSA by comparing physician-defined target boundaries to MRI measurements of temperature distributions, thermal dose distributions, and acute treatment-induced perfusion defect., To evaluate the subsequent safety, oncological, and quality-of-life outcomes of these patients for a period of 5 years.

—

Countries

Finland

Outcome results

None listed